Glial Fibrillary Acidic Protein is a Robust Biomarker in Cerebrospinal Fluid and Peripheral Blood After Traumatic Spinal Cord Injury: a Prospective Pilot Study

Overview

Journal Acta Neurochir (Wien)

Specialty Neurosurgery

Date 2023 Feb 15

PMID 36790588

Authors

Thea Overgaard Wichmann

Helge Kasch

Stig Dyrskog

Kristian Hoy

Bjarne Kuno Moller

Jan Krog

Hans Jurgen Hoffmann

Claus Vinter Bodker Hviid

Mikkel Mylius Rasmussen

Affiliations

Soon will be listed here.

Abstract

Purpose: Biochemical biomarkers to determine the injury severity and the potential for functional recovery of traumatic spinal cord injury (TSCI) are highly warranted; however, it remains to be clarified whether cerebrospinal fluid (CSF) or peripheral blood (PB) is the ideal sample media. This study aims to measure and compare biomarker concentrations in CSF and PB and to explore associations between biomarker concentrations and injury severity, i.e., American Spinal Injury Association (ASIA) Impairment Scale (AIS) grade, and biomarker concentrations and clinical outcome, i.e., AIS grade improvement and Spinal Cord Independent Measure version III (SCIM-III) score.

Methods: From 2018 to 2020, we conducted a single-center prospective pilot study of TSCI patients (n=15) and healthy controls (n=15). Sample collection and clinical outcome assessment were performed at median 13 h [IQR: 19], 9 days [IQR: 2], and 148 days [IQR: 49] after TSCI. Concentrations of neuron-specific enolase (NSE); glial fibrillary acid protein (GFAP); neurofilament light chain (NfL); interferon-γ (IFN-γ); interleukin (IL)-1ß, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, and IL-13; and tumor necrosis factor α (TNF-α) were measured and associated to clinical outcomes.

Results: The biomarker concentrations were higher in CSF than PB. CSF concentrations of GFAP, NSE, IFN-y, TNF-a, IL-2, IL-12p70, IL-4, IL-10, and IL-13 and PB concentrations of GFAP and IFN-y were significantly associated with AIS grade, but not with AIS grade improvement or SCIM-III score.

Conclusions: Our results support GFAP as a potential diagnostic biomarker that may be measured in CSF as well as PB.

Citing Articles

MRI variables and peripheral inflammatory response biomarkers predict severity and prognosis in patients with acute cervical traumatic spinal cord injury.

Ding Z, Zhou W, Wang D, Li L, Wang C, Wang C BMC Musculoskelet Disord. 2024; 25(1):900.

PMID: 39533270 PMC: 11558895. DOI: 10.1186/s12891-024-08038-0.

Axonal Growth and Fasciculation of Spinal Neurons Promoted by Aldynoglia in Alkaline Fibrin Hydrogel: Influence of Tol-51 Sulfoglycolipid.

Buzoianu-Anguiano V, Arriero-Cabanero A, Fernandez-Mayoralas A, Torres-Llacsa M, Doncel-Perez E Int J Mol Sci. 2024; 25(17).

PMID: 39273121 PMC: 11395328. DOI: 10.3390/ijms25179173.

Admission levels of serum biomarkers have additive and cumulative prognostic value in traumatic brain injury.

Kaaber I, Lesbo M, Wichmann T, Olsen D, Rasmussen M, Brink O Sci Rep. 2024; 14(1):14139.

PMID: 38898030 PMC: 11187066. DOI: 10.1038/s41598-024-64125-1.

References

Abdelhak A, Foschi M, Abu-Rumeileh S, Yue J, DAnna L, Huss A . Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. 2022; 18(3):158-172. DOI: 10.1038/s41582-021-00616-3. View

Albayar A, Roche A, Swiatkowski P, Antar S, Ouda N, Emara E . Biomarkers in Spinal Cord Injury: Prognostic Insights and Future Potentials. Front Neurol. 2019; 10:27. PMC: 6361789. DOI: 10.3389/fneur.2019.00027. View

Anderson K . Targeting recovery: priorities of the spinal cord-injured population. J Neurotrauma. 2005; 21(10):1371-83. DOI: 10.1089/neu.2004.21.1371. View

Biglari B, Swing T, Child C, Buchler A, Westhauser F, Bruckner T . A pilot study on temporal changes in IL-1β and TNF-α serum levels after spinal cord injury: the serum level of TNF-α in acute SCI patients as a possible marker for neurological remission. Spinal Cord. 2015; 53(7):510-4. DOI: 10.1038/sc.2015.28. View

Cao F, Yang X, Liu W, Hu W, Li G, Zheng X . Elevation of neuron-specific enolase and S-100beta protein level in experimental acute spinal cord injury. J Clin Neurosci. 2008; 15(5):541-4. DOI: 10.1016/j.jocn.2007.05.014. View

Casha S, Rice T, Stirling D, Silva C, Gnanapavan S, Giovannoni G . Cerebrospinal Fluid Biomarkers in Human Spinal Cord Injury from a Phase II Minocycline Trial. J Neurotrauma. 2018; 35(16):1918-1928. DOI: 10.1089/neu.2018.5899. View

Casmiro M, Maitan S, de Pasquale F, Cova V, Scarpa E, Vignatelli L . Cerebrospinal fluid and serum neuron-specific enolase concentrations in a normal population. Eur J Neurol. 2005; 12(5):369-74. DOI: 10.1111/j.1468-1331.2004.01021.x. View

Dalkilic T, Fallah N, Noonan V, Elizei S, Dong K, Belanger L . Predicting Injury Severity and Neurological Recovery after Acute Cervical Spinal Cord Injury: A Comparison of Cerebrospinal Fluid and Magnetic Resonance Imaging Biomarkers. J Neurotrauma. 2017; 35(3):435-445. DOI: 10.1089/neu.2017.5357. View

Davies A, Hayes K, Dekaban G . Clinical correlates of elevated serum concentrations of cytokines and autoantibodies in patients with spinal cord injury. Arch Phys Med Rehabil. 2007; 88(11):1384-93. DOI: 10.1016/j.apmr.2007.08.004. View

10.

Du W, Li H, Sun J, Xia Y, Zhu R, Zhang X . The Prognostic Value of Serum Neuron Specific Enolase (NSE) and S100B Level in Patients of Acute Spinal Cord Injury. Med Sci Monit. 2018; 24:4510-4515. PMC: 6057265. DOI: 10.12659/MSM.907406. View

11.

Elizei S, Kwon B . The translational importance of establishing biomarkers of human spinal cord injury. Neural Regen Res. 2017; 12(3):385-388. PMC: 5399708. DOI: 10.4103/1673-5374.202933. View

12.

Fernandez M, Baldassarro V, Capirossi R, Montevecchi R, Bonavita J, Cescatti M . Possible Strategies to Optimize a Biomarker Discovery Approach to Correlate with Neurological Outcome in Patients with Spinal Cord Injury: A Pilot Study. J Neurotrauma. 2019; 37(3):431-440. DOI: 10.1089/neu.2018.6362. View

13.

Bernardo Harrington G, Cool P, Hulme C, Osman A, Chowdhury J, Kumar N . Routinely Measured Hematological Markers Can Help to Predict American Spinal Injury Association Impairment Scale Scores after Spinal Cord Injury. J Neurotrauma. 2020; 38(3):301-308. PMC: 7826437. DOI: 10.1089/neu.2020.7144. View

14.

Hayakawa K, Okazaki R, Ishii K, Ueno T, Izawa N, Tanaka Y . Phosphorylated neurofilament subunit NF-H as a biomarker for evaluating the severity of spinal cord injury patients, a pilot study. Spinal Cord. 2012; 50(7):493-6. DOI: 10.1038/sc.2011.184. View

15.

Hayes K, Hull T, Delaney G, Potter P, Sequeira K, Campbell K . Elevated serum titers of proinflammatory cytokines and CNS autoantibodies in patients with chronic spinal cord injury. J Neurotrauma. 2002; 19(6):753-61. DOI: 10.1089/08977150260139129. View

16.

Heller R, Raven T, Swing T, Kunzmann K, Daniel V, Haubruck P . CCL-2 as a possible early marker for remission after traumatic spinal cord injury. Spinal Cord. 2017; 55(11):1002-1009. DOI: 10.1038/sc.2017.69. View

17.

Itzkovich M, Gelernter I, Biering-Sorensen F, Weeks C, Laramee M, Craven B . The Spinal Cord Independence Measure (SCIM) version III: reliability and validity in a multi-center international study. Disabil Rehabil. 2007; 29(24):1926-33. DOI: 10.1080/09638280601046302. View

18.

Kenward M, Roger J . Small sample inference for fixed effects from restricted maximum likelihood. Biometrics. 1997; 53(3):983-97. View

19.

Kuhle J, Gaiottino J, Leppert D, Petzold A, Bestwick J, Malaspina A . Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. J Neurol Neurosurg Psychiatry. 2014; 86(3):273-9. DOI: 10.1136/jnnp-2013-307454. View

20.

Kwon B, Bloom O, Wanner I, Curt A, Schwab J, Fawcett J . Neurochemical biomarkers in spinal cord injury. Spinal Cord. 2019; 57(10):819-831. DOI: 10.1038/s41393-019-0319-8. View